Translation

Notice: This document is a translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.

.

October 14, 2026

To Whom It May Concern:

Company Name: Daito Pharmaceutical Co., Ltd.
Representative: Hiroshi Matsumori, President and CEO
(Securities Code: 4577, Prime Market of Tokyo Stock Exchange)
Inquiries: Kenji Otsuga, Director, Executive Officer and CFO
(Telephone Number: +81-76-421-5665)

Notice Concerning the Acquisition of Treasury Shares and the Cancellation of Treasury Shares

(The acquisition of treasury shares based on the Articles of Incorporation pursuant to Article 459, Paragraph 1 of the Companies Act, and the cancellation of treasury shares pursuant to Article 178 of the Companies Act)

Daito Pharmaceutical Co., Ltd. (the "Company") hereby announces that, at the meeting of the Board of Directors held on October 14, 2026, the Company resolved to acquire treasury shares pursuant to Article 459, Paragraph 1 of the Companies Act and the Articles of Incorporation, and to cancel treasury shares pursuant to Article 178 of the Companies Act, as outlined below.

1. Reason for acquisition of treasury shares

The Company will acquire treasury shares as part of its capital policy under the Medium-Term Management Plan, with the aim of enhancing shareholder returns and improving capital efficiency.

2. Details of acquisition

(1)	Class of shares to be acquired:	Common stock of the Company
(2)	Total number of shares to be acquired:	Up to 1,250,000 shares (Equivalent to 4.4% of the total number of shares issued, excluding treasury shares)
(3)	Total acquisition cost of shares:	Up to 2,000 million yen
(4)	Acquisition period:	From October 15, 2026 to May 21, 2027
(5)	Method of acquisition: auction	Planned to be conducted through market purchases on the on the Tokyo Stock Exchange

3. Details of cancellation of treasury shares

(1)	Class of shares to be cancelled:	Common stock of the Company
(2)	Total number of shares to be cancelled:	1,250,000 shares (planned) (Equivalent to 4.4% of the total number of shares issued, excluding treasury shares)
(3)	Scheduled cancellation date:	May 31, 2027

(Reference) Treasury shares held as of September 30, 2026

Total number of shares outstanding (excluding treasury shares):28,354,162 shares

Number of treasury shares: 500,718 shares

Note: The above number of treasury shares does not include 94,340 shares of the Company held in trust under the stock delivery trust for Board Directors.

End